North Dakota State Investment Board’s Axsome Therapeutics AXSM Stock Holding History

North Dakota State Investment Board’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$311K	Buy	+1,271	New	+$276K	0.01%	666

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

North Dakota State Investment Board's AXSM Position: Q2 2026 in Review

North Dakota State Investment Board opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 1,271 shares worth $311K. The stake represents 0.01% of the portfolio and ranks #666 among its holdings.

504 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

North Dakota State Investment Board held 1,271 shares of Axsome Therapeutics worth $311K as of Q2 2026.
Axsome Therapeutics was a new North Dakota State Investment Board position in Q2 2026.
Axsome Therapeutics made up 0.01% of North Dakota State Investment Board's portfolio in Q2 2026, its #666 holding.
504 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on North Dakota State Investment Board's 13F filing for Q2 2026, filed 4 Aug 2026.